Clinical Experts and Entrepreneurs to Converge on Cleveland to Discuss Broad-Based Strategies for Reducing Chronic Disease

CLEVELAND, Feb. 25, 2014 /PRNewswire/ -- Cleveland HeartLab Inc., a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its Fifth Annual Symposium titled, "Where Inflammation Meets Lipids®: Broad-Based Strategies for Chronic Disease Prevention," will focus on treating and preventing chronic disease. The symposium will be held this year at the Renaissance Hotel in Cleveland on September 12-13 and will include a reception at the Rock and Roll Hall of Fame.

(Logo: http://photos.prnewswire.com/prnh/20140205/CL59890LOGO )

"Chronic disease consumes seventy-five cents of every health-care dollar spent today, yet in many cases it is preventable," said Jake Orville, president and chief executive of Cleveland HeartLab. "This year's symposium will focus on broad-based strategies for identifying and preventing chronic disease, keeping patients healthier and lowering health-care costs. This is the fifth year of Cleveland HeartLab's annual symposium, which demonstrates our continuing commitment to innovation, education and the promotion of early risk identification and disease prevention. We're thrilled with the thought leaders who are speaking at this year's event, representing the foremost experts in cardiology, diabetes and metabolic disease."  

CHL's symposium is a medical education event dedicated to chronic disease prevention and mitigation. The annual event attracts several hundred of the best clinicians from the United States focused in cardiology, metabolic disease, diabetes and other chronic disease states.

"Cleveland HeartLab has helped redefine the way we look at heart disease," said Seth J. Baum, MD, FACC, Medical Director at Women's Preventive Cardiology at Boca Raton Regional Hospital and a speaker at the 2014 symposium. "When the consensus in the field said cholesterol was the primary risk factor, Cleveland HeartLab helped prove that cholesterol is just one important piece of a complex cardiovascular-disease puzzle in which inflammation plays a pivotal role. We now know that half of all patients who suffer from heart attacks have 'normal' cholesterol levels. Cleveland HeartLab was well ahead of this learning curve and its annual conference is a perfect platform to provide education for prevention-orientated physicians and specialists. The symposium provides leading-edge insight on how best to approach cardiovascular disease prevention, as well as the myriad of predominantly inflammation-related chronic conditions."

Experts speaking this year include leading practitioners in primary care and integrative and functional medicine who focus on wellness and prevention. This year's program is also attracting corporate leaders with comparable goals, such as improving employee health and reducing costs. In addition to panel discussions, attendees will be able to participate in a unique case study session designed to maximize attendee participation. 

In addition to the case study program, Mike Miller, MD, FACC, FAHA, Director of Preventive Cardiology at the University of Maryland Medical Center will discuss the role of music and medicine.  Following Dr. Miller's talk, attendees will be invited to a special reception at the Rock and Roll Hall of Fame.

Another featured speaker, Ian Shakil, CEO of Augmedix, will discuss how technology is revolutionizing everyday medical care.  Mr. Shakil's talk will highlight the application of Google Glass in a primary care setting.  Attendees will have the unique opportunity to experience Google Glass.

In addition to these two great talks, other highlight speakers include:

Christie Ballantyne, MD, FACC, FACP, Chief, Cardiovascular Research Section, Baylor College of Medicine

Annie Goldberg, MD, FACP, FAHA, FNLA, President, Foundation of National Lipid Association and Chair, NLA Expert Panel on Familial Hypercholesterolemia

James Januzzi, MD, Director, Cardiac Intensive Care Unit, Mass General and Professor of Medicine, Harvard School of Medicine

Paul Grundy, MD, MPH, Global Director, Healthcare Transformation, IBM and President, Patient-Centered Primary Care Collaborative

Peter McCullough, MD MPH, FACC, Chair, National Kidney Foundation, Kidney Early Evaluation Program

Erin Martin, DO, MPH, author and founder of TrueMed Institute

Philip Schauer, MD, Chief, Minimally Invasive Surgery and Director, Bariatric and Metabolic Institute, Cleveland Clinic

Neal Barnard, MD, famous author and founder of the Physicians Committee for Responsible Medicine

Shilpa Saxena, M.D., founder, SevaMed Institute

To learn more and to register, visit the symposium website: www.clevelandheartlab.com/who-we-are/events/symposium/

About Cleveland HeartLab

Cleveland HeartLab Inc. is an advanced clinical laboratory and cardiovascular disease management company. Established in 2009, CHL offers an array of proprietary testing and analysis focused on the identification and reduction of cardiovascular inflammation. The company operates a CLIA-certified and CAP-accredited national clinical laboratory. CHL has developed prognostic tests based on unique molecular biomarkers which are used by thousands of medical practitioners for better prediction of risk beyond standard risk factors such as cholesterol testing. CHL also has an innovative research and development group that is tasked with the discovery and commercial development of next-generation cardiovascular biomarkers for utilization through the company's clinical laboratory. This valuable research-enabled pipeline of tests and testing services is part of CHL's novel intellectual property portfolio that targets large under-served markets. For more information, visit us at www.clevelandheartlab.com.

SOURCE Cleveland HeartLab Inc.